Status:
UNKNOWN
Role of Macrophage Migratory Inhibitory Factor in Systemic Sclerosis
Lead Sponsor:
Assiut University
Conditions:
System; Sclerosis
Eligibility:
All Genders
17-70 years
Brief Summary
Migration Inhibitory Factor has proliferative and antiapoptotic actions on fibroblasts which may be relevant to scleroderma because of the central role of a dysregulated fibroproliferative response in...
Detailed Description
* Systemic sclerosis (scleroderma) is a disease of unknown etiology characterized by fibrosis of the skin and internal organs, pronounced vasculopathy, and dysregulated immune system. * Clinically, th...
Eligibility Criteria
Inclusion
- Patients with Systemic Sclerosis .
Exclusion
- Patients with Interstitial Pulmonary Fibrosis caused by causes other than SSc.
- Other rheumatologic diseases.
- Overlap or Mixed diseases.
- Patients with renal disease caused by causes other than SSc.
- Unwillingness to participate in the study.
Key Trial Info
Start Date :
September 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03268330
Start Date
September 1 2021
End Date
November 1 2021
Last Update
January 12 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University Hospital
Asyut, Egypt
2
Assuit University hospital
Asyut, Egypt